Verrica Pharmaceuticals Inc.VRCA
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · verrica.com
Dermatology-focused therapeutics company based in West Chester, Pennsylvania. Develops and commercializes YCANTH for molluscum contagiosum and is running pivotal trials in common warts.
Key ratios
FCF / Sales
-44.0%TTM
2025
-49.5%2024
-805.6%2023
-759.9%
Net margin
-102.8%TTM
2025
-50.3%
ROA
-44.0%TTM
2025
-14.7%2024
-60.6%2023
-62.6%
ROE
-240.4%2025
2024
-1546.6%2023
-224.1%
Revenue growth
106.2%TTM
2025
370.2%2024
47.7%2023
-43.3%
Recent news
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027
Track VRCA in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer